1. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality (21 CFR 211.84(d)(1) and 211.84(d)(2)). You failed to ensure that incoming lots of active pharmaceutical ingredient (API) were suitable for use in manufacturing your over-the-counter (OTC) drug products intended for the U.S. market.